$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc

$53.94

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

12/24/2024: CRNX (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Historic Profit: -3.54%	Upturn Advisory Performance 2	Avg. Invested days: 44
Profits based on simulation	Stock Returns Performance 1	Last Close 12/24/2024

Type: Stock	Today’s Advisory: PASS
Historic Profit: -3.54%	Avg. Invested days: 44
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 12/24/2024	Upturn Advisory Performance 2

Key Highlights

Company Size Mid-Cap Stock	Market Capitalization 5.00B USD
Price to earnings Ratio -	1Y Target Price 75.07
Dividends yield (FY) -	Basic EPS (TTM) -3.7
Volume (30-day avg) 739004	Beta 0.62
52 Weeks Range 33.67 - 62.53	Updated Date 12/24/2024

Company Size Mid-Cap Stock	Market Capitalization 5.00B USD	Price to earnings Ratio -	1Y Target Price 75.07
Dividends yield (FY) -	Basic EPS (TTM) -3.7	Volume (30-day avg) 739004	Beta 0.62
52 Weeks Range 33.67 - 62.53	Updated Date 12/24/2024

Earnings Date

Report Date -	When -
Estimate -	Actual -

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -29525.22%

Management Effectiveness

Return on Assets (TTM) -24.29%

Return on Equity (TTM) -40.26%

Valuation

Trailing PE -	Forward PE -
Enterprise Value 4193993352	Price to Sales(TTM) 4814.5
Enterprise Value to Revenue 4036.57	Enterprise Value to EBITDA -13.4
Shares Outstanding 92737600	Shares Floating 91419825
Percent Insiders 1.8	Percent Institutions 94.69

Trailing PE -	Forward PE -	Enterprise Value 4193993352	Price to Sales(TTM) 4814.5
Enterprise Value to Revenue 4036.57	Enterprise Value to EBITDA -13.4	Shares Outstanding 92737600	Shares Floating 91419825
Percent Insiders 1.8	Percent Institutions 94.69

Analyst Ratings

Rating 4.5	Target Price 46.89	Buy 5
Strong Buy 8	Hold 1	Sell -
Strong Sell -

Rating 4.5	Target Price 46.89	Buy 5	Strong Buy 8
Hold 1	Sell -	Strong Sell -

AI Summarization

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX): Comprehensive Analysis

Company Profile:

History and Background:

Founded in 2006 by industry veterans with extensive drug discovery and development expertise.
Focused initially on developing therapies for endocrine disorders and women’s health.
Recently transitioned to a targeted drug discovery platform specializing in oral, small-molecule therapies.

Core Business Areas:

Research & Development (R&D):
- Oral medications for the treatment of acromegaly and other endocrine disorders.
- Pioneering the design of non-peptidal somatostatin receptor agonists.

Leadership Team:

CEO: Scott Struthers, Ph.D.
CFO: Timothy Coughlin
Chief Medical Officer: Michael Walker, M.D.
Experienced team with proven success in biopharmaceuticals.

Top Products and Market Share:

Top Products:

Somatuline Autogel: Injectable drug for acromegaly (acquired from Ipsen).
Oral somatostatin receptor agonist (currently in Phase 3 development).

Market Share:

Somatuline Autogel: Dominant market share for injectable acromegaly treatment in the US.
Oral somatostatin receptor agonist: Potential to capture significant share in the growing oral acromegaly market.

Products Compared:

Oral Somatostatin receptor agonist: Offers potential advantages over injectable options, including improved convenience, compliance, and patient satisfaction.

Total Addressable Market:

Global acromegaly market estimated at roughly USD 1 billion in 2022.
Significant unmet needs exist for more convenient and tolerable treatment options.

Financial Performance:

Revenue and EPS:

Revenue: Modest revenue from Somatuline Autogel sales.
EPS: Current operating expenses preclude positive earnings.

Financial Health:

Strong balance sheet with cash reserves to fund operations through 2024.
Anticipating future revenue and profitability with upcoming drug launches.

Dividends and Shareholder Returns:

No current dividend payout due to investment focus on R&D and growth.
Shareholder returns primarily driven by stock price appreciation.

Growth Trajectory:

Historical Growth:

Achieved significant milestones in recent years, including successful Phase 2 trials and advancement of oral somatostatin receptor agonist candidate.

Future Prospects:

Potential blockbuster drug with oral somatostatin receptor agonist.
Continued development of innovative therapies for acromegaly and related disorders.
Strategic acquisitions and partnerships to enhance pipeline and expand market reach.

Market Dynamics:

Industry Trends:

Growing demand for non-invasive and convenient treatments for chronic conditions.
Increased adoption of targeted therapies with fewer side effects.

Company Positioning:

Early adopter of oral targeted therapy approach for endocrine disorders.
Strong R&D capabilities and experienced team.

Competitors:

Novartis (NVS): Sandoz division, market share leader for injectable acromegaly treatments.
Ipsen (IPN): Former partner, previously marketed Somatuline Autogel.
Kyowa Kirin (4151.T): Tempol, another oral somatostatin receptor agonist in development.

Competitive Advantage:

Oral somatostatin receptor agonist offers potential differentiation in a crowded market.

Challenges and Opportunities:

Key Challenges:

Competition from established players.
Regulatory hurdles for new drug approvals.
Continued R&D investment needed for pipeline expansion.

Key Opportunities:

First-mover advantage with oral somatostatin receptor agonist.
Growing market for acromegaly and other endocrine disorders.
Potential for strategic acquisitions and partnerships.

Recent Acquisitions (last 3 years):

No significant acquisitions in the past 3 years.

AI-Based Fundamental Rating:

Rating: 7 out of 10

Justification:

Strong growth potential based on promising pipeline.
Experienced leadership and strong financial position.
Potential risks include competition and regulatory uncertainties.

Sources:

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice.
Please consult with a qualified financial advisor before making any investment decisions.

Upturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Crinetics Pharmaceuticals Inc

Exchange	NASDAQ	Headquaters	San Diego, CA, United States
IPO Launch date	2018-07-18	Founder, President, CEO & Director	Dr. R. Scott Struthers Ph.D.
Sector	Healthcare	Website	https://www.crinetics.com
Industry	Biotechnology	Full time employees	290
Headquaters	San Diego, CA, United States
Founder, President, CEO & Director	Dr. R. Scott Struthers Ph.D.
Website	https://www.crinetics.com
Website	https://www.crinetics.com
Full time employees	290

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.

Crinetics Pharmaceuticals Inc (CRNX)CRNX